Related Experiment Videos
[Tiotropium. A new anti-cholinergic agent for treatment of chronic obstructive pulmonary disease]
Steffen Thirstrup Pedersen1, Peter Lange
1Lungemedicinsk Klinik, H:S Hvidovre Hospital, DK-2650 Hvidovre.
Abstract:
Tiotropium is a new anti-cholinergic drug with a long duration of action designed for maintenance treatment of chronic obstructive pulmonary disease (COPD). Tiotropium is the first drug specifically developed for the treatment of COPD, but it is also amongst the most expensive drugs used for this condition. The clinical pharmacology of tiotropium and results from published controlled clinical trials are reviewed. It is concluded that tiotropium seems suitable as a symptomatic treatment for patients with moderate to severe COPD (typically a forced expiratorical volume FEV1 < 50% of the predicted volume), who despite optimal use of short acting bronchodilators still suffer from severe symptoms.
Related Concept Videos
Antiasthma Drugs: Muscarinic Receptor Antagonists
Antimuscarinic agents compete with ACh for the same binding site on the muscarinic receptors. By binding to these receptors, they inhibit the downstream effects of ACh and block the parasympathetic...
Cholinergic Antagonists: Therapeutic Uses
Respiratory Tract: Ipratropium, aclidinium, and tiotropium treat asthma, chronic bronchitis, and chronic obstructive pulmonary disease (COPD). They protect against bronchoconstriction caused by irritants like cigarette smoke, sulfur dioxide, and ozone. They also help reduce nasopharyngeal secretions in common...
Cholinergic Antagonists: Pharmacokinetics
COPD: Management Using Bronchodilators and Corticosteroids
Direct-Acting Cholinergic Agonists: Therapeutic Uses
Chronic Obstructive Pulmonary Disease-V: Management
Smoking Cessation